Serabelisib is under clinical development by Millennium Pharmaceuticals and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.

According to GlobalData, the latest event to affect Serabelisib’s likelihood of approval (LoA) and phase transition for Solid Tumor took place on 27 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.

GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Serabelisib Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.

Serabelisib overview

Serabelisib (TAK-117, INK1117) is under development for solid tumors, metastatic triple negative breast cancer, squamous Cell Carcinoma, transitional cell carcinoma, adenocarcinoma of colon and rectum, endometrial cancer, ovarian cancer, endometrioid adenocarcinoma, serous adenocarcinoma, undifferentiated carcinoma, clear cell adenocarcinoma, mixed epithelial carcinoma, mucinous adenocarcinoma, carcinosarcoma and endometrial carcinoma. It is administered through oral route in the form of capsule and tablet. It acts by targeting the PI3Kalpha isoform. It was under development for the treatment of advanced solid tumor malignancies including squamous non-small cell lung cancer, relapsed and refractory gastric cancer, metastatic clear cell renal cell carcinoma and adenocarcinoma of the gastroesophageal junction.

Millennium Pharmaceuticals overview

Millennium Pharmaceuticals is a biopharmaceutical company that offers cancer therapy for the treatment of patients with multiple myeloma and relapsed mantle cell lymphoma. It is headquartered in Cambridge, Massachusetts, the US.

Quick View Serabelisib LOA Data

Report Segments
  • Innovator
Drug Name
  • Serabelisib
Administration Pathway
  • Oral
Therapeutic Areas
  • Oncology
Key Developers
Highest Development Stage
  • Phase II

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.